Literature DB >> 24531536

Stem cell characteristics in glioblastoma are maintained by the ecto-nucleotidase E-NPP1.

J Bageritz1, L Puccio1, R M Piro2, V Hovestadt1, E Phillips1, T Pankert3, J Lohr4, C Herold-Mende4, P Lichter1, V Goidts1.   

Abstract

Glioblastomas are highly aggressive brain tumours and are characterised by substantial cellular heterogeneity within a single tumour. A sub-population of glioblastoma stem-like cells (GSCs) that shares properties with neural precursor cells has been described, exhibiting resistance to therapy and therefore being considered responsible for the high recurrence rate in glioblastoma. To elucidate the underlying cellular processes we investigated the role of phosphatases in the GSC phenotype, using an in vitro phosphatome-wide RNA interference screen. We identified a set of genes, the knockdown of which induces a significant decrease in the glioma stem cell marker CD133, indicating a role in the glioblastoma stem-like phenotype. Among these genes, the ecto-nucleotidase ENPP1 (ectonucleotide pyrophosphatase/phosphodiesterase 1) was found to be highly expressed in GSCs compared with normal brain and neural stem cells. Knockdown of ENPP1 in cultured GSCs resulted in an overall downregulation of stem cell-associated genes, induction of differentiation into astrocytic cell lineage, impairment of sphere formation, in addition to increased cell death, accumulation of cells in G1/G0 cell cycle phase and sensitisation to chemotherapeutic treatment. Genome-wide gene expression analysis and nucleoside and nucleotide profiling revealed that knockdown of ENPP1 affects purine and pyrimidine metabolism, suggesting a link between ENPP1 expression and a balanced nucleoside-nucleotide pool in GSCs. The phenotypic changes in E-NPP1-deficient GSCs are assumed to be a consequence of decreased transcriptional function of E2F1. Together, these results reveal that E-NPP1, by acting upstream of E2F1, is indispensable for the maintenance of GSCs in vitro and hence required to keep GSCs in an undifferentiated, proliferative state.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24531536      PMCID: PMC4013511          DOI: 10.1038/cdd.2014.12

Source DB:  PubMed          Journal:  Cell Death Differ        ISSN: 1350-9047            Impact factor:   15.828


  60 in total

Review 1.  Deconstructing stem cell self-renewal: genetic insights into cell-cycle regulation.

Authors:  Keith W Orford; David T Scadden
Journal:  Nat Rev Genet       Date:  2008-02       Impact factor: 53.242

Review 2.  Trophic functions of nucleotides in the central nervous system.

Authors:  Joseph T Neary; Herbert Zimmermann
Journal:  Trends Neurosci       Date:  2009-03-11       Impact factor: 13.837

3.  CD133 negative glioma cells form tumors in nude rats and give rise to CD133 positive cells.

Authors:  Jian Wang; Per Ø Sakariassen; Oleg Tsinkalovsky; Heike Immervoll; Stig Ove Bøe; Agnete Svendsen; Lars Prestegarden; Gro Røsland; Frits Thorsen; Linda Stuhr; Anders Molven; Rolf Bjerkvig; Per Ø Enger
Journal:  Int J Cancer       Date:  2008-02-15       Impact factor: 7.396

4.  Glioma stem cell lines expanded in adherent culture have tumor-specific phenotypes and are suitable for chemical and genetic screens.

Authors:  Steven M Pollard; Koichi Yoshikawa; Ian D Clarke; Davide Danovi; Stefan Stricker; Roslin Russell; Jane Bayani; Renee Head; Marco Lee; Mark Bernstein; Jeremy A Squire; Austin Smith; Peter Dirks
Journal:  Cell Stem Cell       Date:  2009-06-05       Impact factor: 24.633

5.  Cancer stem cell analysis and clinical outcome in patients with glioblastoma multiforme.

Authors:  Roberto Pallini; Lucia Ricci-Vitiani; Giuseppe Luigi Banna; Michele Signore; Dario Lombardi; Matilde Todaro; Giorgio Stassi; Maurizio Martini; Giulio Maira; Luigi Maria Larocca; Ruggero De Maria
Journal:  Clin Cancer Res       Date:  2008-12-15       Impact factor: 12.531

6.  SSEA-1 is an enrichment marker for tumor-initiating cells in human glioblastoma.

Authors:  Myung Jin Son; Kevin Woolard; Do-Hyun Nam; Jeongwu Lee; Howard A Fine
Journal:  Cell Stem Cell       Date:  2009-05-08       Impact factor: 24.633

7.  A genome-wide RNAi screen identifies a new transcriptional module required for self-renewal.

Authors:  Guang Hu; Jonghwan Kim; Qikai Xu; Yumei Leng; Stuart H Orkin; Stephen J Elledge
Journal:  Genes Dev       Date:  2009-04-01       Impact factor: 11.361

8.  Integration of external signaling pathways with the core transcriptional network in embryonic stem cells.

Authors:  Xi Chen; Han Xu; Ping Yuan; Fang Fang; Mikael Huss; Vinsensius B Vega; Eleanor Wong; Yuriy L Orlov; Weiwei Zhang; Jianming Jiang; Yuin-Han Loh; Hock Chuan Yeo; Zhen Xuan Yeo; Vipin Narang; Kunde Ramamoorthy Govindarajan; Bernard Leong; Atif Shahab; Yijun Ruan; Guillaume Bourque; Wing-Kin Sung; Neil D Clarke; Chia-Lin Wei; Huck-Hui Ng
Journal:  Cell       Date:  2008-06-13       Impact factor: 41.582

9.  JASPAR, the open access database of transcription factor-binding profiles: new content and tools in the 2008 update.

Authors:  Jan Christian Bryne; Eivind Valen; Man-Hung Eric Tang; Troels Marstrand; Ole Winther; Isabelle da Piedade; Anders Krogh; Boris Lenhard; Albin Sandelin
Journal:  Nucleic Acids Res       Date:  2007-11-15       Impact factor: 16.971

Review 10.  The 2007 WHO classification of tumours of the central nervous system.

Authors:  David N Louis; Hiroko Ohgaki; Otmar D Wiestler; Webster K Cavenee; Peter C Burger; Anne Jouvet; Bernd W Scheithauer; Paul Kleihues
Journal:  Acta Neuropathol       Date:  2007-07-06       Impact factor: 17.088

View more
  23 in total

1.  Silencing of CtBP1 suppresses the migration in human glioma cells.

Authors:  Chengjin Zhao; Yifen Shen; Xuelei Tao; Jian Xu; Junjie Lu; Chao Liu; Zhiwei Xu; Qing Tang; Tao Tao; Xiubing Zhang
Journal:  J Mol Histol       Date:  2016-05-09       Impact factor: 2.611

2.  A sub-pathway based method to identify candidate drugs for glioblastomas.

Authors:  Yong-ri Zheng; Kai Kang; Jian-jiao Wang
Journal:  Med Oncol       Date:  2014-08-22       Impact factor: 3.064

3.  Functional characterization of ENPP1 reveals a link between cell cycle progression and stem-like phenotype in glioblastoma.

Authors:  Josephine Bageritz; Violaine Goidts
Journal:  Mol Cell Oncol       Date:  2014-12-23

4.  MiR-136 targets E2F1 to reverse cisplatin chemosensitivity in glioma cells.

Authors:  Wanghao Chen; Yong Yang; Bo Chen; Peisong Lu; Liping Zhan; Qiang Yu; Kan Cao; Qiaoyu Li
Journal:  J Neurooncol       Date:  2014-08-20       Impact factor: 4.130

5.  Development of Novel Ecto-Nucleotide Pyrophosphatase/Phosphodiesterase 1 (ENPP1) Inhibitors for Tumor Immunotherapy.

Authors:  Xiang Wang; Xing Lu; Daojing Yan; Yajun Zhou; Xiangshi Tan
Journal:  Int J Mol Sci       Date:  2022-06-26       Impact factor: 6.208

Review 6.  Nucleotide pyrophosphatase/phosphodiesterase 1 (NPP1) and its inhibitors.

Authors:  Sang-Yong Lee; Christa E Müller
Journal:  Medchemcomm       Date:  2017-02-09       Impact factor: 3.597

7.  Glioblastoma: a pathogenic crosstalk between tumor cells and pericytes.

Authors:  Elisabetta M Caspani; Philip H Crossley; Carolina Redondo-Garcia; Salvador Martinez
Journal:  PLoS One       Date:  2014-07-17       Impact factor: 3.240

8.  Pediatric and Adult High-Grade Glioma Stem Cell Culture Models Are Permissive to Lytic Infection with Parvovirus H-1.

Authors:  Rafael Josupeit; Sebastian Bender; Sonja Kern; Barbara Leuchs; Thomas Hielscher; Christel Herold-Mende; Jörg R Schlehofer; Christiane Dinsart; Olaf Witt; Jean Rommelaere; Jeannine Lacroix
Journal:  Viruses       Date:  2016-05-19       Impact factor: 5.048

9.  p73 promotes glioblastoma cell invasion by directly activating POSTN (periostin) expression.

Authors:  Vivien Landré; Alexey Antonov; Richard Knight; Gerry Melino
Journal:  Oncotarget       Date:  2016-03-15

10.  HOXB1 Is a Tumor Suppressor Gene Regulated by miR-3175 in Glioma.

Authors:  Liang Han; Dehua Liu; Zhaohui Li; Nan Tian; Ziwu Han; Guang Wang; Yao Fu; Zhigang Guo; Zifeng Zhu; Chao Du; Yu Tian
Journal:  PLoS One       Date:  2015-11-13       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.